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Abstract Objective: To measure the in vivo variations of
CYP3A activity induced by anti-HIV drugs in human
immunodeﬁciency virus (HIV)1-positive patients.
Methods: A low oral dose of midazolam (MID)
(0.075 mg) was given to the patients and the 30-min total
1-OH midazolam (1-OHMID)/MID ratio was deter-
mined. Patients were phenotyped either before the
introduction of antiretroviral treatments (control group,
90 patients) or after a variable period of antiretroviral
treatment (56 patients). Twenty-one subjects underwent
multiple phenotyping tests (before and during the course
of the treatment).
Results: The median MID ratio was 3.51 in the control
group (range 0.20–14.6). It was 5-fold higher in the group
with efavirenz (28 patients; median, range: 16.0, 3.81–
367; P<0.0001), 13-fold lower with nelﬁnavir (18 pa-
tients; 0.27, 0.06–36.3; P<0.0001), 17-fold lower with
efavirenz+ritonavir (three patients; 0.21, 0.05–0.47;
P=0.006), 50-fold lower with ritonavir (four patients;
0.07, 0.06–0.17; P=0.0007), and 7-fold lower with nevi-
rapine+(ritonavir or nelﬁnavir or grapefruit juice) (three
patients; 0.48, 0.03–1.83; P=0.03). CYP3A activity was
lower in the efavirenz+ritonavir group (P=0.01) and in
the ritonavir group (P=0.04) than in the nelﬁnavir
group, although already strongly inhibited in the latter.
Conclusion: The low-dose MID phenotyping test was
successfully used to measure the in vivo variations of
CYP3A activity induced by antiretroviral drugs.
Efavirenz strongly induces CYP3A activity, while riton-
avir almost completely inhibits it. Nelﬁnavir strongly
decreases CYP3A activity, but to a lesser extent than
ritonavir. The inhibition of CYP3A by ritonavir or
nelﬁnavir oﬀsets the inductive eﬀects of efavirenz or
nevirapine administered concomitantly. Finally, no
induction of CYP3A activity was noticeable after
long-term administration of ritonavir at low dosages
(200 mg/day b.i.d.) or of nelﬁnavir at standard dosages
(2,500 mg/day b.i.d.).
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Introduction
During previous years, signiﬁcant advances have been
made in the pharmacological treatment of human
immunodeﬁciency virus (HIV) infections using highly
active antiretroviral strategy. In such therapy, protease
inhibitors (PIs) are routinely coadministered with other
antiretroviral drugs [nucleosidic reverse transcriptase
inhibitors (NRTI), non-nucleosidic reverse transcriptase
inhibitors (NNRTI), and other PIs]. The rational basis
for combination therapy with drugs having diﬀerent
mechanisms of action is to obtain an additive or syner-
gistic inhibition of HIV replication and prevention of the
emergence of drug-resistant strains. PIs and NNRTIs,
unlike NRTIs, are extensively metabolized by cyto-
chrome P450 (CYP) isozymes present in the liver and in
the gut wall. Among these isozymes, CYP3A, a term
that in adults reﬂects the collective activity of CYP3A4
and CYP3A5, is the most important but other isozymes
such as CYP2C9, CYP2C19, CYP2D6, and CYP2B6
also contribute [1, 2]. Nevirapine and efavirenz, two
NNRTIs, induce drug-metabolizing enzymes, including
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CYP3A [1]. Most PIs are inhibitors of CYP3A, ritonavir
being the most potent, and saquinavir the least [3, 4]. A
strong inhibition of CYP3A by ritonavir represents a
potential clinical problem, considering the multiple
pharmacotherapy often received by HIV-positive pa-
tients, but it is also the basis for combination treatment
with other PIs such as amprenavir, indinavir, saquinavir,
and lopinavir in order to increase their plasma concen-
trations [5, 6].
Interestingly, ritonavir, amprenavir and nelﬁnavir
are both CYP3A inhibitors and inducers, and thus in-
duce their own metabolism [5, 7, 8]. The phenomenon
of concurrent inhibition and induction of drug metab-
olism by PIs represents a potential clinical problem as
its outcome may be time dependent, a short exposure
to the drug producing an inhibition that is potentially
oﬀset by induction after long-term exposure [8, 9].
However, few studies, with mixed results, measured
speciﬁcally CYP3A activity during the time course of
antiretroviral treatment. One phenotyping study found
that neither dapsone hydroxylation nor cortisol 6b-
hydroxylation detected the inhibition of CYP3A by
HIV-1 protease inhibitors such as ritonavir, indinavir,
or amprenavir administered for 3–4 weeks to 18 pa-
tients [10]. In patients infected with HIV, the results of
the erythromycin breath test were not diﬀerent among
a group of ﬁve patients receiving drugs reported to
induce CYP3A activity (nevirapine, dexamethasone), a
group of eight patients receiving drugs reported to in-
hibit CYP3A activity (clarithromycin, ﬂuconazole,
sertraline, ﬂuoxetine, itraconazole), and a group of
eight patients receiving drugs reported to induce and
inhibit CYP3A (nevirapine, phenytoin, rifabutine,
ﬂuconazole, ﬂuoxetine) [11]. However, nevirapine
administered for 14 days signiﬁcantly increased the
median erythromycin breath test by 22% [11], and
delavirdine decreased by 70–75% the predose erythro-
mycin breath test values after both short- and
long-term administration [12]. In a fourth study, uri-
nary 6b-hydroxycortisol measured in HIV-positive
pregnant women was comparable to that determined in
the urine of healthy subjects, although the patients were
all treated with PIs such as indinavir and nelﬁnavir [13],
which are CYP3A inhibitors [4]. Finally, efavirenz
signiﬁcantly increased the mean erythromycin breath
test result in a dose- and time-dependent manner (55%
mean induction at 400 mg and 33% induction at
200 mg) in two groups of 12 healthy subjects receiving
200 mg/day or 400 mg/day for 10 days [14].
Some hypotheses have been put forward to tenta-
tively explain these mixed results [10–14]. Multiple
CYP isozymes play a role in the metabolism of dap-
sone, and it is not clear whether CYP3A is the sole
metabolic pathway for the 6b-hydroxylation of cortisol
[10]. The erythromycin breath test, a well-validated
CYP3A probe, measures the activity of hepatic but
not of intestinal CYP3A, the latter being diﬀerently
regulated than the former [15]. A strong inhibition of
anti-HIV drugs on intestinal, but not hepatic, CYP3A
would therefore not be detected by this test. Finally,
erythromycin is a substrate of the permeability glyco-
protein (PGP), and how the PGP/CYP3A alliance
would ultimately aﬀect drug’s metabolism [16, 17], and
the results of the above-mentioned study with eryth-
romycin as a CYP34 probe are still unclear [11, 12,
14].
The biotransformation of midazolam (MID) to its
major metabolite, 1-OH midazolam (1-OHMID), is
mediated by CYP3A [18]. We recently validated the use
of the 1-OHMID/MID ratio determined 30 min after the
administration of a very low oral dose of MID
(0.075 mg) as a marker of CYP3A activity [19]. The aim
of the present study was to determine variations of
CYP3A activity induced by various anti-HIV drugs using
the low-dose MID phenotyping test and to assess the
potential of this test in the follow-up of drug inﬂuences
on CYP3A activity.
Subjects and methods
Clinical study
HIV-1-infected patients were recruited in a study on the
inﬂuence of genetic factors on the response to antiret-
roviral treatment [20]. The choice of antiretroviral
treatment was made independently from the study.
Some preliminary results on the low-dose MID pheno-
typing test in HIV-1 positive patients treated with ef-
avirenz and nelﬁnavir have been presented in a previous
report [20], with MID ratios calculated with free (un-
conjugated) MID and OHMID concentrations. How-
ever, as the use of total (conjugated+unconjugated)
MID and OHMID, measured after enzymatic hydrolysis
of the glucuronide, enables the removal of the interin-
dividual variability of the glucuroconjugation from the
MID ratios [19, 21], samples were reanalyzed to deter-
mine total MID and OHMID concentrations. Patients
declared to be free of any MID containing drugs, and it
was also checked that the measured plasma levels of
MID and OHMID were compatible with the adminis-
tration of the low MID dose used for the phenotyping
test (data not shown).
Patients were either phenotyped before the intro-
duction of antiretroviral treatments (90 patients, 52
without comedications, 38 with comedications, none of
the comedications known as being a CYP3A inhibitor or
inducer) or after a variable period of antiretroviral
treatment (56 patients). Among the former, 21 subjects
agreed to undergo multiple phenotyping tests, i.e., be-
fore and during the course of the treatment. For these
patients, the ﬁrst MID phenotyping test was made on
day zero, before initiation of antiretroviral treatment
(which was started the same day, after the test). Second
and third tests were planned after 1 day and 1 month of
treatment, respectively. Data from four patients having
undergone multiple phenotyping tests were excluded
because of non-compliance shown by non-detectable
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blood levels of the antiretroviral agents of interest (three
patients) and discrepancy between the date of the phe-
notyping test indicated on the tube of blood and on the
case report form (one patient). Patients gave their writ-
ten informed consent to participate in the study, which
was approved by the ethics committee of the ‘‘Centre
Hospitalier Universitaire Vaudois’’ (Faculty of Medi-
cine).
MID phenotyping test
Patients were asked to drink 100 ml water containing
0.075 mg MID, prepared by diluting 75 ll of a 1-mg/ml
MID solution into 100 ml water. The patients then
drunk an additional 100 ml water used for rinsing the
glass. A blood sample was drawn 30 min later to
determine the OHMID/MID ratio. The timing of the test
was not controlled with regard to the timing of food
ingestion. However, a decrease of MID absorption by
food was not expected to inﬂuence the results, as a
metabolite/mother substance ratio was calculated, and as
the ratio obtained 30 min after MID intake was equiva-
lent to the ratio obtained 1 h after MID ingestion [19].
Determinations of plasma concentrations of MID,
1-OHMID and of anti-HIV drugs
Plasma MID and OHMID concentrations were deter-
mined as total drug (conjugated+non-conjugated) by
means of gas chromatography–negative chemical
ionization mass spectrometry [22], after enzymatic
hydrolysis of the glucuronic conjugates as previously
described [22]. The limit of quantiﬁcation was 10 pg/ml
both for MID and for OHMID [22]. No interference
from antiretroviral drugs was noted during the MID
assay (data not shown). MID ratios were calculated as
the metabolite over the parent drug blood levels mul-
tiplied by 325.8 and divided by 341.8 (the former and
the latter values being the molecular weights of MID
and OHMID, respectively). In the group of 90 patients
phenotyped before starting the antiretroviral treatment,
blood levels of total OHMID were below the limit of
quantiﬁcation for one patient. In the group of 56
patients phenotyped while on treatment, blood levels of
MID and of total OHMID were below the limit of
quantiﬁcation for ﬁve patients on efavirenz, and for
seven patients on PIs, respectively. For these patients,
the limit of quantiﬁcation of the method, i.e., 10 pg/ml,
was used for calculating the MID ratios.
Determination of plasma concentrations of efavirenz,
ritonavir, and nelﬁnavir was performed using high-per-
formance liquid chromatography (HPLC) [23]. For
correlations between the MID ratios and plasma con-
centrations of efavirenz and nelﬁnavir, results were ex-
pressed as percentile distribution on the basis of our
database, which included measurements of more than
4,000 drug concentrations.
Statistical analysis
The Mann-Whitney U-test, the Spearman correlation
test and the Wilcoxon matched paired test were used
when appropriate (Statistica, Release 4.5., Statsoft, Loll
& Nielsen, Hamburg, Germany). The two-sample bi-
nomial test of equal proportion was used for compar-
isons of frequencies. A P value lower than 0.05 was
considered as statistically signiﬁcant.
Results
Table 1 presents a summary of clinical data. The groups
of HIV-positive patients studied before the introduction
of antiretroviral treatments (n=90, group A) and on
antiretroviral treatments (n=56) did signiﬁcantly diﬀer
with regard to age, time in treatment, and proportion of
males. Figure 1 shows the MID ratios in the groups of
patients studied before the introduction of antiretroviral
treatments and on antiretroviral treatments. In the latter
group, 28 patients received efavirenz (group 1), 18 pa-
tients nelﬁnavir (group 2), 3 patients efavirenz+ritona-
vir (group 3), 4 patients ritonavir (group 4), and 3
patients nevirapine (group 5; in this last group, one
subject received a combination of nevirapine and nelﬁ-
navir, a second a combination of nevirapine, ritonavir,
amprenavir, and lopinavir, while a third did not receive
other PIs or NNRTIs but had been drinking grapefruit
juice for the 3 days preceding the test). In the group of
subjects phenotyped prior to antiretroviral treatment
(n=90, group A), patients without comedications
(n=52, group A1) did not signiﬁcantly diﬀer from pa-
tients with comedications (38 patients, group A2), with
regard to gender, age, and MID ratio. Data from the
whole group were therefore used as control for statistical
comparisons of MID ratios with antiretroviral-treated
groups.
CYP3A activity diﬀered signiﬁcantly between each
group of antiretroviral-treated patients and the control
group. The median MID ratios were thus 5-fold higher
(P<0.0001), 13-fold lower (P<0.0001), 17-fold lower
(P=0.006), 50-fold lower (P=0.0007), and 7-fold lower
(P=0.03) in the group of patients receiving efavirenz,
nelﬁnavir, efavirenz+ritonavir, ritonavir, and nevira-
pine, respectively, when compared with the control
group. Although already inhibited by nelﬁnavir, CYP3A
activity was signiﬁcantly lower in the efavirenz+riton-
avir group (P=0.01) and in the ritonavir group
(P=0.04) than in the nelﬁnavir group. Removing the
data of the outlier did not change the results (data not
shown). In the three patients receiving nevirapine, the
highest MID ratio was measured in the patient taking
grapefruit juice (1.83), the lowest in the patient with ri-
tonavir+amprenavir+lopinavir (0.03), with an inter-
mediate value in the patient with nelﬁnavir (0.48). In the
group of 28 and 18 patients treated with efavirenz and
nelﬁnavir, respectively, there were no signiﬁcant corre-
lations between MID ratios and blood concentrations of
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efavirenz (r=0.02; P=0.93) and nelﬁnavir (r=0.18;
P=0.47), respectively.
Midazolam ratios measured in patients having
undergone multiple phenotyping tests are shown in
Fig. 2. The last MID test, performed after a median
period of treatment of 29 days (range 8–125 days),
corresponds to steady-state levels for the administered
antiretroviral drugs. Eleven patients received efavirenz
600 mg/day q.d. (Fig. 2a) for a median period of
30 days (range 21–125 days). Other anti-HIV drugs
prescribed to this group included zidovudine and/or
lamivudine and/or stavudine and/or abacavir. Efavirenz
treatment resulted in a 2.9-fold increase of median MID
ratio (P<0.005), but with a large variability (range of
increase: 1.4–103-fold). A signiﬁcant correlation was
noted between the increase of CYP3A activity and the
mean CYP3A activity, i.e., (MID ratio after treatment
+ MID ratio at baseline)/2 (r2=0.48, P=0.019), i.e., a
Table 1 Clinical data and 1-OH midazolam/midazolam ratios, determined using total 1-OH midazolam and midazolam (MID)
concentrations, measured in diﬀerent groups of HIV-1-positive patients
Group of patients Clinical data Statistical comparisons of MID ratios
between groups
Group A: patients before antiretroviral treatment with and without comedications P<0.0001 Group A versus group 1
Number of patients and gender 90 patients, 58 men P<0.0001 Group A versus group 2
Age (years: median; range) 37; 19–73 P=0.006 Group A versus group 3
MID ratio (median; range) 3.51; 0.20–14.6 P=0.0007 Group A versus group 4
P=0.03 Group A versus group 5
Group A1: patients before antiretroviral treatment without comedications NS Group A1 versus group A2
Number of patients and gender 52 patients, 32 men
Age (years: median; range) 37; 19–61
MID ratio (median; range) 3.42; 0.24–14.6
Group A2: patients before antiretroviral treatment with comedications
Number of patients and gender 38 patients, 26 men
Age (years: median; range) 38; 23–73
MID ratio (median; range) 3.52; 0.20–14.5
Group 1: patients with efavirenz 600 mg/day q.d.
Number of patients and gender 28 patients, 20 men P<0.0001 Group 1 versus group 2
Duration of treatment (days: median; range) 285; 21–1218 P=0.005 Group 1 versus group 3
Age (years: median; range) 39; 20–74 P=0.001 Group 1 versus group 4
MID ratio (median; range) 16.0; 3.81–367 P=0.005 Group 1 versus group 5
Other antiretroviral treatment
(number of patients)
Zidovudine (20), lamivudine (25),
stavudine (7), didanosine (2),
abacavir (2)
Group 2: patients with nelﬁnavir 2500 mg/day b.i.d.
Number of patients and gender 18 patients, 5 men P=0.01 Group 2 versus group 3
Duration of treatment (days: median; range) 714; 12–1288 P=0.04 Group 2 versus group 4
Age (years: median; range) 42; 34–59 NS Group 2 versus group 5
MID ratio (median; range) 0.27; 0.06–36.3
Other antiretroviral treatment
(number of patients)
Saquinavir (2), zidovudine (9),
lamivudine (17), stavudine (8),
Group 3: patients with efavirenz 600 mg/day q.d. and ritonavir 200 mg/day b.i.d.
Number of patients and gender 3 patients, 2 men NS Group 3 versus group 4
Duration of treatment (days: median; range) 26; 24–28 NS Group 3 versus group 5
Age (years: median; range) 41; 35–51
MID ratio (median; range) 0.21; 0.05–0.47
Other antiretroviral treatment
(number of patients)
Lopinavir (3), amprenavir (1),
stavudine (1), didanosine (1)
Group 4: patients with ritonavir (200 mg/day b.i.d., 2 patients; 800/day, b.i.d., 2 patients)
Number of patients and gender 4 patients, 3 men NS Group 4 versus group 5
Duration of treatment (days: median; range) 429; 28–1130
Age (years: median; range) 49; 42–68
MID ratio (median; range) 0.07; 0.06–0.17
Other antiretroviral treatment
(number of patients)
Indinavir (1), amprenavir (1),
saquinavir (2), lopinavir (1),
zidovudine (1), lamivudine (1),
stavudine (3)
Group 5: patients with nevirapine (200 mg/day b.i.d., 1 patient; 400 mg/day, q.d., 2 patients)
Number of patients and gender 3 patients, 2 men
Duration of treatment (days: median; range) 484; 153–1144
Age (years: median; range) 54; 49–71
MID ratio (median; range) 0.48; 0.03–1.83
Other antiretroviral treatment
(number of patients)
Nelﬁnavir (1), ritonavir (1),
amprenavir (1), lopinavir (1),
zidovudine (1), lamivudine (2),
stavudine (1)
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higher increase of CYP3A activity was observed in
patients with a low CYP3A baseline activity. There was
no correlation between the increase of CYP3A activity
and the plasma concentrations of efavirenz (r=0.02,
P=0.96). A trend was observed when correlating the
percentage increase of CYP3A activity and the duration
of treatment (r=0.60, P=0.051). Four patients were
also phenotyped after the ﬁrst dose: an increase of
CYP3A activity (up to 2.6-fold) was measured in three
of them at the second phenotyping test.
Two patients received efavirenz 600 mg/day q.d. and
ritonavir 200 mg/day b.i.d. (Fig. 2b). These two patients
received other anti-HIV drugs—as lopinavir and/or
amprenavir and/or didanosine. A strong reduction in
CYP3A activity was measured in these two patients,
shown by a MID ratio decrease to 8% and 12% of the
original value after 28 days and 42 days of treatment,
respectively. Two patients receiving ritonavir without
efavirenz (Fig. 2c; other anti-HIV drugs prescribed: in-
dinavir and/or amprenavir and/or lopinavir and/or
zidovudine and/or lamivudine and/or stavudine). In
these two patients, an almost complete inhibition of
CYP3A activity was measured after 1 month of treat-
ment (CYP3A activity: 2% and 1% of the baseline va-
lue). In the patient on ritonavir+efavirenz phenotyped
on day 1, a 3.5-fold increase of MID ratio was observed
between the test performed on day 1 and day 28,
reﬂecting the increase in CYP3A activity. However, in
the two patients on ritonavir without efavirenz, a further
decrease (2.0-fold and 4.7-fold) of MID ratios was ob-
served between the second and the third tests, showing a
further decrease of CYP3A activity despite the strong
inhibition already observed during the ﬁrst day of
treatment. Finally, in two patients receiving nelﬁnavir
with no other PI or NNRT (other anti-HIV drugs re-
Fig. 1 Total 1-OH midazolam/midazolam ratios in diﬀerent
groups of HIV-1-positive patients. Group A: patients without
antiretroviral treatment, with and without comedications; group
A1: patients without antiretroviral treatment, without comedica-
tions; and group A2: patients without antiretroviral treatment, with
comedications. Group 1: patients with efavirenz; group 2: patients
with nelﬁnavir; group 3: patients with efavirenz+ritonavir; group
4: patients with ritonavir; and group 5: patients with nevirapine and
other protease inhibitors or grapefruit juice. The median value in
each group is indicated by a line
Fig. 2 1-OH midazolam/midazolam (MID) ratios, determined by
using total 1-OHMID and MID concentrations, in HIV-1 positive
patients receiving various antiretroviral treatments (a efavirenz, b
efavirenz+ritonavir, c ritonavir, d nelﬁnavir) measured on three
occasions (ﬁrst visit: before treatment, second visit: after 1 or
2 days of treatment, third visit: after at least 8 days of treatment)
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ceived: zidovudine and/or lamivudine, and/or stavudine)
(Fig. 2d), a marked decrease of CYP3A activity was also
noted, reﬂected by a MID ratio decrease to 4% of the
baseline value after 8 days and 48 days of treatment.
Discussion
Drug interaction with PIs and NNRTIs is mediated
through interactions with several proteins, including the
PGP [24, 25] and with isoforms of the CYP family [1,
2]. With regard to the latter, an inhibition and/or
induction of CYPA4 by PIs and NNRTIs is probably a
core mechanism through which interactions occur. In
the present study, HIV-positive patients without anti-
retroviral drugs (control group) and those treated with
PIs (ritonavir and nelﬁnavir) and NNRTIs (efavirenz
and nevirapine) were phenotyped with a low dose of
MID. The statistical diﬀerences observed among the
diﬀerent groups (duration of treatment, proportion of
men, age of patients) have to be discussed when com-
paring MID ratios among these groups. With regard to
the variable duration of treatment between groups, all
56 patients can be considered in steady-state conditions,
as the shortest duration of treatment was 12 days.
Concerning the diﬀerence of age, the median age in the
control group was 37 years, while it was 42, 49 and
54 years in the nelﬁnavir-, ritonavir-, and nevirapine-
treated groups, respectively. Ontogeny in CYP3A is
well known, and small variations of CYP3A activity
occur during aging. [26, 27]. However, these variations
are much smaller than those observed in the present
study, i.e., it is very unlikely that the abovementioned
diﬀerences of age could explain the large variations of
CYP3A activity observed between diﬀerent groups of
treatments. Finally, with regard to the high proportion
of female patients observed in the nelﬁnavir group
compared with the other groups, this should not
inﬂuence CYP3A activity, as there is no statistical
diﬀerence in MID clearance between men and
women [28].
For the present study, MID ratios were calculated
with total but also with free OHMID concentrations.
The use of free MID ratios results in more overlapping
values between the groups (data not shown). This dif-
ference is most probably explained by the removal of the
interindividual variability linked to glucuroconjugation
[19, 21] when using total concentrations. Thus, only
total MID ratios are presented and discussed. Among
HIV-positive patients without antiretroviral treatment,
MID ratios were not signiﬁcantly diﬀerent between
subjects with and without comedications. This result was
expected, as none of the comedications was known to be
a CYP3A inducer or inhibitor. However, the range of
MID ratios appears to be wider in this group than in a
group of healthy subjects without comedications (MID
ratios between 2 and 11 were measured in a group of 13
healthy subjects [19]). This result is in agreement with
another study that found that variability in hepatic
activity of CYP3A measured using the erythromycin
breath test may be greater in HIV-positive patients than
in controls subjects [11]. In the present study, low MID
ratios (i.e., around unity and lower) were measured in
several HIV-positive patients, with or without comedi-
cations (Fig. 1). Such low ratios suggest an inhibited
CYP3A activity, as values between 0.40 and 1.2 were
measured in four healthy subjects treated with ketoco-
nazole, a strong CYP3A inhibitor, 400 mg/day for
2 days [19]. Several hypotheses can be put forward to
explain the low CYP3A activity observed in some
HIV-positive patients. First, although the comedications
received by these patients are not known as CYP3A
inhibitors, several of them are CYP3A substrates (data
not shown), and they might therefore inhibit to some
extent the activity of this isozyme. Second, about
one-sixth of the patients contracted HIV through
intravenous drug use, and the inﬂuence of a possible
consumption of illicit drugs at the time of the pheno-
typing test is unknown. Finally, certain viral infections
including HIV stimulate cytokine production, and these
infections could suppress activity of CYP enzymes [11].
During initial preclinical studies, efavirenz was shown
to induce its own metabolism and to increase activities
of CYP3A in rats, rhesus monkeys, and humans (Bris-
tol-Myers Squibb, unpublished data, July 2000) [29].
This has recently been conﬁrmed by a study in healthy
subjects that found a dose-dependent induction of
hepatic but not intestinal CYP3A4 by efavirenz [14]. The
present study also conﬁrms the induction of CYP3A by
efavirenz, as the MID ratio was signiﬁcantly higher
(ﬁvefold) in the efavirenz-treated patients than in the
control group. Among patients who underwent multiple
phenotyping tests, the administration of efavirenz for a
minimum period of 3 weeks resulted in an induction of
CYP3A activity in all patients, with a median threefold
increase of the MID ratio. A very large interindividual
variability was observed in the increase of CYP3A
activity, which can be explained, at least in part, by the
baseline activity of this isozyme, i.e., a higher increase of
CYP3A activity is observed in patients with a low
CYP3A baseline activity. However, no clear explanation
can, at present, be given for the trend toward signiﬁ-
cance when correlating the percentage increase and the
number of days of treatment, with a negative correlation
value (i.e., the longer is the treatment with efavirenz, the
lowest is the increase in CYP3A activity). However, one
can formulate the hypothesis that a reduced compliance
during long-term treatment could contribute to this re-
sult or, alternatively, an autoinduction of efavirenz
metabolism during long-term treatment could ﬁrst con-
tribute to lower efavirenz plasma concentrations,
resulting subsequently in a decrease of CYP3A induc-
tion.
In the present study, unlike a previous report [14],
no correlation was observed between the increase
of CYP3A activity and the plasma concentrations of
efavirenz. Presently, no explanations can be given for
this discrepancy, but both studies diﬀered by many
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factors, such as the type of subjects included (HIV po-
sitive patients versus healthy subjects), the dose of ef-
avirenz (200 or 400 versus 600 mg/day), and the
duration of treatment (10 days versus median duration
of 285 days). Also, in the above-mentioned study, the
increase of erythromycin breath test was statistically
signiﬁcant after 4 days of efavirenz at 400 mg/day (eight
subjects), but not with efavirenz at 200 mg/day (eight
subjects) [14]. In the present study, an increase of
CYP3A activity was already noticeable after 1 day of
treatment with efavirenz at 600 mg/day, i.e., after a
single dose, in three of four patients. Due to the low
number of subjects, this result could, however, be for-
tuitous, and such a rapid induction of CYP3A by the
administration of 600 mg/day efavirenz needs to be
conﬁrmed by other studies. Finally, the lack of corre-
lation between CYP3A activity and efavirenz plasma
levels determined in the present study is in agreement
with the above-mentioned study, which suggested that
CYP2B6, and not CYP3A, represents the most impor-
tant pathway for elimination of this drug in humans [14].
Three patients received nevirapine, a CYP3A inducer
[1]. However, the MID ratios suggested a slight (one
patient) or a strong (two patients) inhibition of CYP3A
activity. The former case can most probably be ex-
plained by the consumption of grapefruit juice, a
CYP3A inhibitor [30], while the latter by the coadmin-
istration of nelﬁnavir or ritonavir.
Most PIs are inhibitors of CYP3A [3, 4]. This is in
agreement with the present study, which clearly dem-
onstrates a strong and signiﬁcant inhibition of CYP3A
activity by ritonavir and nelﬁnavir, when comparing
data from PI-treated patients to those of the control
group. Interestingly, MID ratios were signiﬁcantly lower
in patients receiving ritonavir (200 mg/day, as a phar-
macokinetic enhancer to increase blood concentrations
of other antiretroviral drugs) than in those receiving
nelﬁnavir (2,500 mg/day), even if efavirenz is coadmin-
istered with ritonavir. This result is in agreement with in
vitro data showing that ritonavir is the most potent
CYP3A inhibitor [3, 4]. In vitro studies showed that
CYP3A4, CYP2D6 and CYP2C19 are the primary en-
zymes involved in the metabolism of nelﬁnavir [31]. In
the present study, no correlation was observed between
MID ratios and nelﬁnavir plasma concentrations. This
could be explained by the fact that, in vivo, CYP3A does
not represent the most important pathway for the
elimination of this drug in humans. However, the fact
that MID hydroxylation was almost completely inhib-
ited by nelﬁnavir does not necessarily mean that
metabolism of nelﬁnavir by CYP3A would also be
completely inhibited.
With regard to the patients who underwent multiple
phenotyping tests, two patients received efavirenz with
ritonavir. In one of these patients, who was pheno-
typed after 1 day and after 28 days of treatment, a
reduction of MID ratios was measured on day 1 rel-
ative to those measured in the baseline test, which
shows that CYP3A is immediately and strongly
inhibited after the ﬁrst dose(s) of ritonavir. Then, the
increase of MID ratio between day 1 and day 28
suggests that induction by efavirenz slightly reverses
this inhibition, although inhibition by ritonavir still
oﬀsets induction by efavirenz, as shown by the
approximate tenfold reduction of the MID ratios be-
tween the baseline test and the test at 1 month. The
treatment of two patients with ritonavir without ef-
avirenz resulted also in a strong decrease of CYP3A
activity as early as after the ﬁrst day(s) of treatment,
followed by an almost complete inhibition of CYP3A
activity after 1 month.
For the present study, the decision to perform a
phenotyping test during the ﬁrst day(s) of drug admin-
istration was motivated, in part, by our intention to
determine whether a possible induction of CYP3A
activity by ritonavir, or other PIs, could be detected after
long-term administration of this drug, compared with a
strong inhibition following the administration of the ﬁrst
dose(s) [9]. This dual mechanism could be a relevant
clinical problem when considering the generalized use of
ritonavir to increase bioavailability and, therefore,
blood concentrations of other antiretroviral drugs. After
the initial phase of CYP3A inhibition by ritonavir, if
induction of this isozyme oﬀsets its inhibition, a decrease
of the plasma concentrations of ritonavir and of the
other drugs might occur, which could lead to reduced
antiviral eﬃcacy. However, as a possible induction of
CYP3A by ritonavir is probably concentration- and
dose dependent, the fact that in combination treatments
ritonavir is usually given at low doses, i.e., around 100–
200 mg/day, should theoretically diminish the potential
problem of CYP3A induction during treatment. In this
study, data obtained in the patients receiving ritonavir
show that, during a long-term treatment, if CYP3A is
induced by this drug, this induction is hidden and does
not oﬀset its strong inhibitory activity, at least with such
low doses. Similar results were obtained with nelﬁnavir
at 2,500 mg/day.
Midazolam is a substrate of CYP3A and probably
also of PGP, although discrepant results have been
published [32, 33]. As PGP is also induced by PIs [8], it
has been suggested that induction of PGP by PIs could
contribute to the lower drug exposure after multiple
doses compared with single doses [8]. Our data showing
a lack of increase of CYP3A activity after long-term
administration of ritonavir and nelﬁnavir are in agree-
ment with the above-mentioned study in rats treated
with PIs, where no increase of hepatic CYP3A activity
was measured using MID as CYP3A substrate, despite
an increase of hepatic CYP3A levels [8]. The present
results are also in agreement with the data we obtained
in the Therapeutic Drug Monitoring Service of the
University Hospital of Lausanne, which show a low
intraindividual variability over time of plasma levels of
PIs and NNRTIs when compliance problems are ex-
cluded and food intake standardized [34, 35]. In the
latter studies, it can however be argued that, as drug
levels were usually ﬁrst measured after 1 month of
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treatment, induction of CYP3A would have already
been complete at that time, which explains that drug
determinations performed later would not diﬀer signiﬁ-
cantly from the ﬁrst blood level [34, 35]. More studies,
are needed to examine the inhibiting/inducing eﬀects of
PIs toward CYP3A activity.
In summary, the present study shows that a low oral
dose of MID can be used to measure the in vivo varia-
tions of CYP3A activity induced by antiretroviral drugs,
despite the fact that either MID or OHMID could not
be detected in a few patients. Efavirenz signiﬁcantly and
strongly induces CYP3A activity, while ritonavir almost
completely inhibits its activity. Nelﬁnavir strongly de-
creases CYP3A activity but to a lesser extent than ri-
tonavir. When administered together, the inhibition of
CYP3A by ritonavir or nelﬁnavir oﬀsets the induction
properties of efavirenz or nevirapine. Finally, no in-
crease of CYP3A activity was noticeable, due to an
induction mechanism, after long-term administration of
ritonavir at low dosages or of nelﬁnavir at standard
dosages. These results are useful for assessing the
activity of CYP3A, a key isozyme involved in the
metabolism of a large number of drugs, in HIV-positive
patients receiving a combination of antiretroviral drugs.
They also support the use of low doses of ritonavir to
increase bioavailability of other antiretroviral drugs,
even on a long-term basis.
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